The Regional Asia Pacific PrEP Webinar will discuss evidence supporting long-acting injectable drug cabotegravir (CAB-LA) from the successful HPTN 083 Study in Thailand and Vietnam, while also discussing implications for combination prevention and other future PrEP products. Representatives from key population communities will share their views on how they envisioned PrEP as HIV combination prevention strategy going forward.
The webinar is intended for civil society organizations, key population communities and other stakeholders who are interested in learning more about new PrEP products and actively participated in generating demand for PrEP in the Asia Pacific region.
The webinar is also prelude to an upcoming regional survey to assess values and preferences for PrEP products. Further coming soon.